Skip to main content
BHVN logo

BHVN · Biohaven Ltd. · Documents

Track BHVN — free
$12.39 -1.26 (-9.23%) At close · Nov 20 Q4 2021 earnings call transcript
Market Cap
$1.87B
Shares
151.06M
Volume · Nov 20 2.39M Avg daily vol (3M) 3.22M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Net loss $738.82M 10-K filed Mar 2, 2026 Quarterly report FY2026 Q3 Net loss $129.28M 10-Q filed Oct 29, 2026 Latest results FDA accepts Vyglxia resubmission for spinocerebellar ataxia 8-K filed Oct 29, 2026 Earnings call Q4 2021 earnings call Held Dec 31, 2021
2026
Nov 16
Current report 8-K
Opakalim enrollment paused as two degrader trials advance

Biohaven Ltd. reports the FDA instructed it to pause new opakalim enrollment under a September 4, 2026 partial clinical hold; BHV-1300 entered Phase 3, while BHV-1400 Phase 3 initiation is planned for 2026.

Regulation FD disclosure Read from the first part of this long document
4 source passages
Biohaven Ltd. The FDA ins tructed Biohaven to pause new enrollment until additional clarifying nonclinical s tudies are completed and issued a partial clinical hold letter on September 4, 2026. Lead MoDE Degrader, BHV-1300 Enters Phase 3 BHV-1400 pivotal trial in IgA nephropathy initiating in 2026 Open the document at this passage
Oct 29
Current report 8-K
FDA accepts Vyglxia resubmission for spinocerebellar ataxia

Biohaven's new drug application resubmission for Vyglxia (troriluzole) in spinocerebellar ataxia was accepted for review by the FDA, with a user fee goal date in the first quarter of 2027. The company reported a net loss of $129.3 million, or $0.86 per share, for the three months ended September 30, 2026. Cash, cash equivalents, marketable securities and restricted cash totaled approximately $164.0 million as of September 30, 2026.

Financial results
4 source passages
The FDA has informed Biohaven that the company’s new drug application resubmission for Vyglxia (troriluzole) in SCA has been accepted for review. has assigned a user fee goal date in the first quarter of 2027 Biohaven reported a net loss for the three months ended September 30, 2026 of $129.3 million, or $0.86 per share Cash, cash equivalents, marketable securities and restricted cash as of September 30, 2026, totaled approximately $164.0 million. Open the document at this passage
Oct 29
Quarterly report 10-Q FY2026 Q3, ended Sep 30
SK Biopharmaceuticals to license Kv7 platform for $400.0 million upfront

In August 2026, Biohaven agreed to license its Kv7 ion channel platform, including BHV-7000, worldwide to SK Biopharmaceuticals. SKBP will pay a non-creditable and non-refundable upfront fee of $400.0 million, $350.0 million at Closing and $50.0 million one year later, plus up to $150.0 million in milestones. An FDA partial clinical hold dated September 4, 2026 pauses new patient enrollment pending additional metabolite nonclinical data.

Net loss $129.28M Diluted EPS -$0.86
Read from the MD&A section
5 source passages
In August 2026, we entered into a License Agreement (the “SKBP License Agreement”) with SK Biopharmaceuticals Co., Ltd. (“SKBP”). to Biohaven’s Kv7 ion channel platform, including BHV-7000 as well as other Kv7 compounds and products covered by the SKBP License Agreement. SKBP will pay us a non-creditable and non-refundable upfront fee of $400.0 million, consisting of $350.0 million payable at the Closing and $50.0 million payable one year after the Closing. Biohaven will also be eligible to receive up to $150.0 million in one-time development and regulatory milestone payments. issued a partial clinical hold letter on September 4, 2026 that pauses new patient enrollment pending the results of additional nonclinical data regarding the metabolite. Open the document at this passage
Oct 22
Current report 8-K
FDA accepts troriluzole SCA resubmission, sets first-quarter 2027 goal date

Biohaven said the FDA accepted its troriluzole resubmission for spinocerebellar ataxia and set a user fee goal date in the first quarter of 2027. The FDA considers the resubmission a complete response to the November 4, 2025 action letter.

Regulation FD disclosure
2 source passages
The FDA has informed Biohaven that the company’s new drug application resubmission for Vyglxia (troriluzole) in SCA has been accepted for review. The FDA communicated that it considers the resubmission a complete response to the November 4, 2025 action letter, and has assigned a user fee goal date in the first quarter of 2027. Open the document at this passage
Oct 15
Current report 8-K Events of Oct 8
Ono licenses IgG degraders for Japan, ASEAN; $80 million upfront

Biohaven entered a Collaboration and License Agreement with Ono Pharmaceutical granting Ono an exclusive, royalty-bearing license to its MoDE pan IgG degrader portfolio in Japan, South Korea, Taiwan and ASEAN countries. Ono will pay an $80 million upfront payment at closing and another $20 million upon a milestone achievement, plus royalties of approximately 20% on net sales. Biohaven keeps rights outside the territory, including the United States, Europe and China.

Entered into a material agreement, Regulation FD disclosure Read from the first part of this long document
7 source passages
entered into a Collaboration and License Agreement (the “License Agreement”) with Ono Pharmaceutical Co., Ltd. (“Ono”) the Company granted Ono an exclusive, royalty-bearing license in Japan, South Korea, Taiwan and the countries of the Association of Southeast Asian Nations (the “Licensed Territory”) Ono will pay the Company a one-time, non-creditable and non-refundable upfront payment of $80 million upon closing another $20 million upon a milestone achievement Ono will pay the Company royalties of approximately 20% on net sales of licensed products in the Licensed Territory The Company retains all rights to the licensed portfolio outside the Licensed Territory, including in the United States, Europe and China. Open the document at this passage
Sep 10
Current report 8-K Events of Sep 4
Other events AI summary on its way
May 5
Current report 8-K Events of May 4
Other events AI summary on its way
Mar 13
Proxy statement DEF 14A Meeting Apr 28, 2026
Proxy statement AI summary on its way
Mar 2
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Net loss $738.82M Diluted EPS -$6.86
Jan 7
Current report 8-K Events of Jan 6
Other events AI summary on its way
2025
2024
Showing 1–50 of 94 documents
Key facts CIK 1935979 CUSIP G1110E107 13F (30d) 298 filings 272 filers Visit website Investor relations